Review: Orlistat and sibutramine are modestly effective for weight loss at 1 year

Padwal, R.
January 2005
ACP Journal Club;Jan/Feb2005, Vol. 142 Issue 1, p19
Academic Journal
The article reports that orlistat and sibutramine are modestly effective for weight loss at one year. Studies of off-label therapy, drugs with high addiction potential that preclude long-term use or investigational, herbal or alternative compounds were excluded. Study quality assessment included method of randomizadon, allocation concealment, blinding, intention-to treat analysis and attrition. Orlistat and sibutramine are modestly effective for weight loss at one year.


Related Articles

  • Review: orlistat and sibutramine are modestly effective for weight loss at 1 year. R., Padwal; Li S.K.; Lou D.C. // Evidence Based Medicine;Feb2005, Vol. 10 Issue 1, p13 

    The article reports that orlistat and sibutramine are modestly effective for weight loss at 1 year. Only trials of orlistat and sibutramine met the selection criteria. 16 Random Clinical Trials (RCTs) (11 of orlistat and 5 of sibutramine) were included. 14 RCTs (11 of orlistat and 3 of...

  • Obesity treatment with a progressive clinical tri-therapy combining sibutramine and a supervised diet—exercise intervention. Bérubé-Parent, S; Prud'homme, D; St-Pierre, S; Doucet, E; Tremblay, A // International Journal of Obesity & Related Metabolic Disorders;Aug2001, Vol. 25 Issue 8, p1144 

    OBJECTIVE: Sibutramine favors a negative energy balance and also has the potential to increase heart rate and blood pressure. We investigated if a progressive supervised sibutramine-diet-exercise clinical intervention could increase the body weight loss previously reported while minimizing the...

  • Multidisciplinary Intervention With Sibutramine: Assessing Successful Weight Loss Predictors in Military Adolescent Dependents. Cabrera, Jorge L.; Wilks, Edward G.; Symons, Jenna E.; Blankson, Kwabena L.; Cole, Renee E. // Military Medicine;Mar2012, Vol. 177 Issue 3, p308 

    Objectives: Assess body mass index (BMI) reduction through a multidisciplinary intervention with sibutramine in adolescents of military parents and examine characteristics and behavioral traits as predictors of successful weight loss. Methods: A prospective study where participants received...

  • ORLISTAT FOR WEIGHT LOSS MAINTENANCE.  // Pulse;5/3/2007, Vol. 67 Issue 17, p42 

    The article focuses on the effect of long-term orlistat in weight loss maintenance among the patients in Great Britain. Study shows that patients weighed between 75 kilogram and 162 kilogram had one or more cardiac risk factors. It was found out that orlistat patients weighed an average 9.4...

  • Antidote. Siegel, Marc // Medical Marketing & Media;Apr2006, Vol. 41 Issue 4, p14 

    The article examines some weight loss drugs in the United States. Xenical or Orlistat are drugs that hinder fat absorption into the gastrointestinal tract. An appetite suppressant, Meridia prevents the reabsorption of serotonin, a hormone in the brain that is released when a patient is full from...

  • The Straight Dope On Weight-Loss Drugs. Fentress, Debbie; Agnew, Bruce // Diabetes Forecast;Apr2002, Vol. 55 Issue 4, p51 

    Provides information on weight-loss drugs, Xenical, Meridia and phentermine. Overview of studies on the drugs; Side effects of weight loss drugs; Contents of the drugs. INSET: Beware herbal remedies.

  • Pharmacotherapy for obesity in menopausal women. Samat, Ashish; Rahim, Asad; Barnett, Anthony // Menopause International;Jun2008, Vol. 14 Issue 2, p57 

    Weight gain, during and after the menopause is common. Contributing factors include ethnicity, reduced physical activity, reduced lean mass, reduced resting metabolic rate and treatment with certain drugs, e.g. steroids, insulin, glitazones. Excess body weight increases the risk of medical...

  • Safety of drug therapies used for weight loss and treatment of obesity. Ioannides-Demos, Lisa L.; Proietto, Joseph; Tonkin, Andrew M.; McNeil, John J. // Drug Safety;2006, Vol. 29 Issue 4, p277 

    Some of the medications used for weight loss in the management of obesity have been associated with unacceptable morbidity and mortality. Safety concerns have led to the withdrawal of aminorex, followed by the fenfluramines in 1997, and phenylpropanolamine (norephedrine) in 2000. Aminorex was...

  • Clinical Pharmacotherapy for Obesity: Current Drugs and Those in Advanced Development. Halford, Jason C. G. // Current Drug Targets;Oct2004, Vol. 5 Issue 7, p637 

    The current obesity pandemic imposes a major global disease burden. Levels of non-communicable diseases such as type 2 diabetes, cardiovascular disease and some cancers will continue to rise unless an effective approach to treat obesity is found. Sustained weight loss of between 5-10% in the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics